Cholangiocarcinoma (CCA) is a cancer that arises from bile ducts/channels draining bile in the liver and often includes the gallbladder cancers. CCA is the second most common form of cancerous liver lesions. In 2017, Linda Kilcrease came to Pashtoon Kasi, MD, MS (then at Mayo Clinic), with metastatic cancer, but it was not amenable or […]
The following is a guest post from Mohammed Milhem, MBBS, Chief of the Section of Oncology. It is part of an ongoing 2019 series of division updates. The Division of Hematology, Oncology and Blood & Marrow Transplantation has grown dramatically over the last 15 years as the care of patients with cancer and blood disorders […]
A recent issue of the New England Journal of Medicine features the results of a multi-site clinical trial in which Dr. Mo Milhem and the University of Iowa’s Holden Comprehensive Cancer Center participated. Sorafenib, a kinase inhibitor primarily used to treat renal, hepatic, and thyroid carcinomas, was used against a placebo in a double-blind, phase […]
For 90 minutes every other week, about a dozen people share a small, comfortable space and talk about their cancer. They talk about how it felt to learn of their diagnosis, they talk about wrangling with insurance companies, they talk about the next round of treatment, they talk about their fear that remission may end. […]
Last year, the Holden Comprehensive Cancer Center (HCCC) at the University of Iowa received its third renewal of its designation as “Comprehensive,” a label that brings with it a great deal of support from the National Institutes of Health’s National Cancer Institute (NCI). This designation recognizes the breadth, leadership, depth, and rigor of the HCCC’s […]
by Tony Craine, Health at Iowa In spring 2015, Trent Phillips of Jesup, Iowa, felt a nagging pain in the back of his left leg that didn’t seem to be getting better. “I thought I had pulled a hamstring,” Trent says. “I had done it before, while playing sports. I told myself, ‘Well, hamstrings take […]